TY - JOUR
T1 - Rare Cancers and Social Media
T2 - Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media—#MPNSM
AU - Pemmaraju, Naveen
AU - Utengen, Audun
AU - Gupta, Vikas
AU - Kiladjian, Jean Jacques
AU - Mesa, Ruben
AU - Thompson, Michael A.
N1 - Funding Information:
Acknowledgements This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672. The authors thank Dr. Matthew Katz and the creators of the Cancer Ontology Tag Program for their inspiration, and the founders and members of Symplur, and the Healthcare Hashtags Project for their continued analysis and support.
Funding Information:
This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672. The authors thank Dr. Matthew Katz and the creators of the Cancer Ontology Tag Program for their inspiration, and the founders and members of Symplur, and the Healthcare Hashtags Project for their continued analysis and support. NP, AU, VG, JJK, RM, and MT collected and analyzed the data and wrote and approved the final manuscript prior to publication. This article is part of the Topical Collection on Social Media Impact of Hematologic Malignancies Naveen Pemmaraju reports honorarium/consulting and/or research/Grant and clinical trial support: Novartis, LFB, Incyte, Stemline, Cellectis, Abbive, Affymetrix, Roche Diagnostics. Dr. Pemmaraju is a section editor for Current Hematologic Malignancy Reports. Vikas Gupta received research grants from Novartis, Incyte, Gilead, and Promedior through his institution, served on scientific advisory board of Novartis, Incyte, and received honorarium from Novartis/Incyte. Audun Utengen is a co-founder of Symplur. Michael A. Thompson has been on Advisory Boards for AIM Specialty Health, BMS, Celgene, Doximity, Takeda, and Via Oncology. MT owns stock in Doximity. He is a peer reviewer for plasma cell dyscrasias for UpToDate and has royalty in UpToDate. J. J. Kiladjian declares no potential conflicts of interest. Ruben Mesa is Editor-in-Chief of Current Hematologic Malignancy Reports.
Funding Information:
Vikas Gupta received research grants from Novartis, Incyte, Gilead, and Promedior through his institution, served on scientific advisory board of Novartis, Incyte, and received honorarium from Novartis/Incyte. Audun Utengen is a co-founder of Symplur.
Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Purpose of review: The use of social media has now become a standard means of communication for many individuals worldwide. The use of one specific form of social media, Twitter, has increased among healthcare providers, both as a means of information gathering and as a conduit for original content creation. Recently, major efforts by users have been put forward to help streamline the unprecedented amount of information that can be found on Twitter. These efforts have led to the creation of diseasespecific hashtag (#) medical communities and have greatly enhanced the ability to understand and better categorize the available data on Twitter. Specifically, for those involved in rare cancer fields, adhering to organically designed and consistently used hashtags has led to the rapid, reliable dissemination of information and the ability to efficiently discuss and debate topics of interest in the field. For the field of myeloproliferative neoplasms (MPNs), the creation of #MPNSM (myeloproliferative neoplasms on social media) in 2015 has facilitated interactions among healthcare stakeholders from all over the world in the MPN field. Recent findings: In order to better understand the trends and topics of interest to Twitter users of this novel medical community, we conducted the present analysis which focuses on Twitter analytics from the first two years of #MPNSM. Summary: In this analysis, we observed a sustained increase in the number of Twitter users, number of tweets, number of impressions, and number of retweets over time, demonstrating the feasibility of creating and maintaining a disease-specific hashtag for a rare cancer over time.
AB - Purpose of review: The use of social media has now become a standard means of communication for many individuals worldwide. The use of one specific form of social media, Twitter, has increased among healthcare providers, both as a means of information gathering and as a conduit for original content creation. Recently, major efforts by users have been put forward to help streamline the unprecedented amount of information that can be found on Twitter. These efforts have led to the creation of diseasespecific hashtag (#) medical communities and have greatly enhanced the ability to understand and better categorize the available data on Twitter. Specifically, for those involved in rare cancer fields, adhering to organically designed and consistently used hashtags has led to the rapid, reliable dissemination of information and the ability to efficiently discuss and debate topics of interest in the field. For the field of myeloproliferative neoplasms (MPNs), the creation of #MPNSM (myeloproliferative neoplasms on social media) in 2015 has facilitated interactions among healthcare stakeholders from all over the world in the MPN field. Recent findings: In order to better understand the trends and topics of interest to Twitter users of this novel medical community, we conducted the present analysis which focuses on Twitter analytics from the first two years of #MPNSM. Summary: In this analysis, we observed a sustained increase in the number of Twitter users, number of tweets, number of impressions, and number of retweets over time, demonstrating the feasibility of creating and maintaining a disease-specific hashtag for a rare cancer over time.
KW - Disease-specific hashtag
KW - Essential thrombocytosis
KW - MPN
KW - Myelofibrosis
KW - Myeloproliferative neoplasm
KW - Polycythemia vera
KW - Social media
KW - Twitter
UR - http://www.scopus.com/inward/record.url?scp=85033446351&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033446351&partnerID=8YFLogxK
U2 - 10.1007/s11899-017-0421-y
DO - 10.1007/s11899-017-0421-y
M3 - Review article
C2 - 29105027
AN - SCOPUS:85033446351
VL - 12
SP - 598
EP - 604
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
SN - 1558-8211
IS - 6
ER -